Do you mean to imply that not only are there other sigma-1 ligands, that might be "agonistic," but they have produced clinical data showing that they are better than the data from blarcamesine?
Again, I invite the posting of such data. Convince those of us who have actually scrutinized and understood the cellular chemistry of blarcamesine that blarcamesine won't cut it; won't be approved by the TGA or the FDA; and the any of the other sigma-1 ligand molecules will.